Callisto Pharmaceuticals Announces Article Citing Atiprimod in Major Scientific News Journal
15 Mayo 2007 - 11:24AM
PR Newswire (US)
History of Atiprimod Appears in Genetic Engineering &
Biotechnology News NEW YORK, May 15 /PRNewswire-FirstCall/ --
Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a
biopharmaceutical company focused on the development of new drugs
to treat cancer and inflammatory diseases, announced today that an
article citing the history of its anti-cancer drug Atiprimod
appeared in Genetic Engineering & Biotechnology News (GEN) (May
1, 2007). Genetic Engineering & Biotechnology News (GEN), the
only high-frequency publication dedicated to biotech news, was
introduced in 1981, as the first biotechnology trade publication.
GEN is now the most widely read bionews publication worldwide. You
may read the article at the following URL. The article in print
also has a Figure image describing the mechanism of action of
atiprimod. The article is available on the Genetic Engineering
& Biotechnology News website at
http://www.genengnews.com/articles/chitem.aspx?aid=2110. About
Callisto Pharmaceuticals, Inc. Callisto is a biopharmaceutical
company focused on the development of new drugs to treat various
forms of cancer and other serious afflictions. Callisto's drug
candidates in development currently include anti-cancer agents in
clinical development, in addition to drugs in pre-clinical
development for other significant health care markets, including
ulcerative colitis. One of the Company's lead drug candidates,
Atiprimod, is in development to treat advanced carcinoid cancer, a
neuroendocrine tumor, and in relapsed or refractory multiple
myeloma, a blood cancer. Atiprimod is currently in a Phase II
clinical trial in advanced carcinoid cancer patients, and in Phase
I/IIa human clinical trials in relapsed or refractory multiple
myeloma patients, respectively. A second anti-cancer drug,
L-Annamycin, is being developed as a treatment for forms of
relapsed or refractory acute leukemia, a currently incurable blood
cancer. L-Annamycin, a new compound from the anthracycline family
of proven anti-cancer drugs, has a novel therapeutic profile,
including activity against resistant diseases and significantly
reduced cardiotoxicity, or damage to the heart, compared to
currently available drug alternatives. Callisto also has drugs in
preclinical development for gastro-intestinal inflammation, and
cancer. Guanilib is the lead candidate of our Guanylate Cyclase
Receptor Agonist (GCRA) platform. Callisto own worldwide patent
coverage for therapeutic applications of Guanilib in cancer and GI
inflammatory diseases. Guanilib is expected to enter clinical trial
in inflammatory bowel disease in 2008. Callisto has exclusive
worldwide licenses from AnorMED Inc. and M.D. Anderson Cancer
Center to develop, manufacture, use and sell Atiprimod and
L-Annamycin, respectively. Callisto is also listed on the Frankfurt
Stock Exchange under the ticker symbol CA4. More information is
available at http://www.callistopharma.com/. Forward-Looking
Statements Certain statements made in this press release are
forward-looking. Such statements are indicated by words such as
"expect," "should," "anticipate" and similar words indicating
uncertainty in facts and figures. Although Callisto believes that
the expectations reflected in such forward-looking statements are
reasonable, it can give no assurance that such expectations
reflected in such forward-looking statements will prove to be
correct. As discussed in the Callisto Pharmaceuticals Form S-3/A
declared effective on February 15, 2007, and its periodic reports,
as filed with the Securities and Exchange Commission, actual
results could differ materially from those projected in the
forward-looking statements as a result of the following factors,
among others: uncertainties associated with product development,
the risk that products that appeared promising in early clinical
trials do not demonstrate efficacy in larger-scale clinical trials,
the risk that Callisto will not obtain approval to market its
products, the risks associated with dependence upon key personnel
and the need for additional financing. DATASOURCE: Callisto
Pharmaceuticals, Inc. CONTACT: Dan D'Agostino of Callisto
Pharmaceuticals, Inc., +1-212-297-0010, ext. 227, or Web site:
http://www.callistopharma.com/
http://www.genengnews.com/articles/chitem.aspx?aid=2110
Copyright